Akihira Mukaiyama

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of <i>HER2</i>-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

Taroh Satoh, Rui‐Hua Xu, Hyun Cheol Chung et al. · Journal of Clinical Oncology · 2014 · 624 citations · Full text

Medicine, Oncology, Pharmacology +15

Degradation of Interleukin 1β by Matrix Metalloproteinases

Akira Itô, Akihira Mukaiyama, Yoshifumi Itoh et al. · Journal of Biological Chemistry · 1996 · 381 citations · Full text

Veterinary Medicine, Cell Biology, Immunology +12

Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.

Taroh Satoh, Yung‐Jue Bang, J. Wang et al. · Journal of Clinical Oncology · 2010 · 35 citations

Medicine, Oncology, Pharmacology +17

Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors

Ken Nakagawa, Haruka Minami, Mineo Kanezaki et al. · Japanese Journal of Clinical Oncology · 2008 · 24 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with <i><scp>BRAF</scp></i> V600 mutation‐positive advanced cutaneous melanoma

Naoya Yamazaki, Arata Tsutsumida, Akira Takahashi et al. · The Journal of Dermatology · 2018 · 22 citations · Full text

Medicine, Oncology, Pharmacology +14